Drug resistance-induced reprogramming of chromatin and transcription factor activity in prostate cancer
Description of the granted funding
The research proposal aims to characterize how activity of transcription factors is changed during development of drug resistance in prostate cancer. Recent years have brought to the market several very effective cancer drugs. Despite this, many times cancer develops resistance against these drugs. We plan to study how transcription factor activity and chromatin landscape changes in drug resistant prostate cancer. Our research uses genome-wide single-cell genomics and single-molecule live cell imaging in cultured cell lines. Modern bioinformatic analyses are used to build a comprehensive model of transcription factor action during prostate cancer drug resistance. This model will be based on single-cell as well as single-molecule data. The obtained results eventually will have a substantial impact on our understanding of how transcription factors mediate drug resistance and generate new cancer therapy options.
Show moreStarting year
2021
End year
2026
Granted funding
Related funding decisions
361974
Research costs of Academy Research Fellows(2024)
195 844 €
346279
Research costs of Academy Research Fellows(2021)
300 000 €
Funder
Research Council of Finland
Funding instrument
Academy research fellows
Other information
Funding decision number
340927
Fields of science
Biochemistry, cell and molecular biology
Research fields
Solu- ja molekyylibiologia
Identified topics
cancer